Pivotal Therapeutics (OTCMKTS:PVTTF – Get Free Report) and Ardelyx (NASDAQ:ARDX – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Pivotal Therapeutics and Ardelyx, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pivotal Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Ardelyx | 1 | 0 | 9 | 1 | 2.91 |
Ardelyx has a consensus target price of $15.73, suggesting a potential upside of 204.79%. Given Ardelyx’s stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than Pivotal Therapeutics.
Institutional & Insider Ownership
Earnings and Valuation
This table compares Pivotal Therapeutics and Ardelyx”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pivotal Therapeutics | N/A | N/A | N/A | N/A | N/A |
| Ardelyx | $407.32 million | 3.13 | -$61.60 million | ($0.23) | -22.43 |
Pivotal Therapeutics has higher earnings, but lower revenue than Ardelyx.
Profitability
This table compares Pivotal Therapeutics and Ardelyx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pivotal Therapeutics | N/A | N/A | N/A |
| Ardelyx | -13.58% | -38.11% | -11.85% |
Summary
Ardelyx beats Pivotal Therapeutics on 7 of the 10 factors compared between the two stocks.
About Pivotal Therapeutics
Pivotal Therapeutics Inc., a specialty pharmaceutical company, focuses on the treatment of cardiovascular diseases and overall health. Its lead product, VASCAZEN, is a prescription only medical food formulated for clinical dietary management of cardiovascular disease in patients with documented coronary heart disease and who are deficient in blood Omega-3 fatty acids, eicosapentaenoic acid, and docosahexanenoic acid levels. The company also offers OMAZEN for the maintenance of good health through elevating Omega-3 fatty acid levels. In addition, the company develops Benefishial product line for overall health, cardiovascular health, prenatal health, toddler’s health, child’s health, and pet’s health. Further, it is developing PVT-100 indicated for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. Pivotal Therapeutics Inc. sells VASCAZEN in the United States and OMAZEN in Canada. The company is headquartered in Woodbridge, Canada.
About Ardelyx
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Pivotal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pivotal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
